Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imatinib Mesylate

FDA-approved product (capsule, oral), marketed as Gleevec, Imatinib Mesylate, Imkeldi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Imatinib Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • B-cell acute lymphoblastic leukemia
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Childhood acute lymphoblastic leukemia
  • Chronic myelogenous leukemia
  • Dermatofibrosarcoma protuberans
  • Gastrointestinal stromal tumor
  • Hypereosinophilic syndrome
  • Lymphoblastic lymphoma
  • Myelodysplastic/myeloproliferative disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Imatinib Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imatinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

    NCT00248482 · start 2002-02

    Registered record
    Registry ID
    NCT00248482
    Conditions
    Lung Cancer
    Interventions
    Cisplatin; Gleevec™; irinotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-02
    Completion
    2008-01
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionCisplatin; Gleevec™; irinotecan
    PhasePhase 2
    Registry statusCompleted

  • Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM

    NCT06038552 · start 2002-01-01

    Registered record
    Registry ID
    NCT06038552
    Conditions
    GIST, Malignant; Liver Metastases
    Interventions
    imatinib (IM); hepatic resection (HR); radiofrequency ablation (RFA); transarterial chemoembolization (TACE)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2002-01-01
    Completion
    2023-05-01
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST, Malignant; Liver Metastases
    Interventionimatinib (IM); hepatic resection (HR); radiofrequency ablation (RFA); transarterial chemoembolization (TACE)
    PhaseNot recorded
    Registry statusCompleted

  • Fludarabine Phosphate and Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib

    NCT00036738 · start 2001-07-13

    Registered record
    Registry ID
    NCT00036738
    Conditions
    Adult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2); BCR-ABL1; Blastic Phase; Childhood Acute Lymphoblastic Leukemia in Remission; Childhood B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2); BCR-ABL1; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase of Disease; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Disease
    Interventions
    Cyclosporine; Dasatinib; Fludarabine Phosphate; Imatinib Mesylate; Mycophenolate Mofetil; Nilotinib; Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation; Peripheral Blood Stem Cell Transplantation; Therapeutic Allogeneic Lymphocytes; Total-Body Irradiation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-07-13
    Completion
    2018-05
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Acute Lymphoblastic Leukemia in Remission; Adult B Acute Lymphoblastic Leukemia With t(9; 22)(q34.1; q11.2) +12 more
    InterventionCyclosporine; Dasatinib; Fludarabine Phosphate; Imatinib Mesylate +6 more
    PhasePhase 2
    Registry statusCompleted

  • Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

    NCT00021229 · start 2001-05

    Registered record
    Registry ID
    NCT00021229
    Conditions
    Brain and Central Nervous System Tumors
    Interventions
    imatinib mesylate; local irradiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2001-05
    Completion
    2008-08
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain and Central Nervous System Tumors
    Interventionimatinib mesylate; local irradiation therapy
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia

    NCT00006343 · start 2000-06

    Registered record
    Registry ID
    NCT00006343
    Conditions
    Leukemia
    Interventions
    recombinant interferon alfa; cytarabine; imatinib mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-06
    Completion
    2007-03
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionrecombinant interferon alfa; cytarabine; imatinib mesylate
    PhasePhase 3
    Registry statusCompleted